SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Godina Christopher)
 

Sökning: WFRF:(Godina Christopher) > Caveolin-1 genotype...

  • Godina, ChristopherLund University,Lunds universitet,Lund Univ, Dept Clin Sci Lund, Div Oncol, Barngatan 4, S-22185 Lund, Sweden.;Skane Univ Hosp, Barngatan 4, S-22185 Lund, Sweden.,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Cancerepidemiologi & strål,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Cancerepidemiology and radiation,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital (författare)

Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • Springer,2023
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-523246
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-523246URI
  • https://doi.org/10.1007/s10549-023-06919-xDOI
  • https://lup.lub.lu.se/record/9e1dc678-15f6-45c7-bcb5-84c45abfe970URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • PurposeCaveolin-1 (CAV1) has been implicated in breast cancer oncogenesis and metastasis and may be a potential prognosticator, especially for non-distant events. CAV1 functions as a master regulator of membrane transport and cell signaling. Several CAV1 SNPs have been linked to multiple cancers, but the prognostic impact of CAV1 SNPs in breast cancer remains unclear. Here, we investigated CAV1 polymorphisms in relation to clinical outcomes in breast cancer.MethodsA cohort of 1017 breast cancer patients (inclusion 2002–2012, Sweden) were genotyped using Oncoarray by Ilumina. Patients were followed for up to 15 years. Five out of six CAV1 SNPs (rs10256914, rs959173, rs3807989, rs3815412, and rs8713) passed quality control and were used for haplotype construction. CAV1 genotypes and haplotypes in relation to clinical outcomes were assessed with Cox regression and adjusted for potential confounders (age, tumor characteristics, and adjuvant treatments).ResultsOnly one SNP was associated with lymph node status, no other SNPs or haplotypes were associated with tumor characteristics. The CAV1 rs3815412 CC genotype (5.8% of patients) was associated with increased risk of contralateral breast cancer, adjusted hazard ratio (HRadj) 4.26 (95% CI 1.86–9.73). Moreover, the TTACA haplotype (13% of patients) conferred an increased risk for locoregional recurrence HRadj 2.24 (95% CI 1.24–4.04). No other genotypes or haplotypes were associated with clinical outcome.ConclusionCAV1 polymorphisms were associated with increased risk for locoregional recurrence and contralateral breast cancer. These findings may identify patients that could derive benefit from more tailored treatment to prevent non-distant events, if confirmed.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Tryggvadottir, HelgaLund University,Lunds universitet,Epidemiologi och farmakogenetik,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Epidemiology and pharmacogenetics,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)med-htg (författare)
  • Bosch, AnaLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Molekylära behandlingsstrategier vid bröstcancer,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Molecular therapeutics in breast cancer,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)med-abp (författare)
  • Borgquist, SigneLund University,Lunds universitet,Bröstcancer - prevention & intervention,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröstcancer,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breast cancer prevention & intervention,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breastcancer,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital,Aarhus University Hospital(Swepub:lu)ront-sbo (författare)
  • Belting, MattiasUppsala University,Lund University,Lunds universitet,Uppsala universitet,Neuroonkologi och neurodegeneration,Science for Life Laboratory, SciLifeLab,Division of Oncology, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Barngatan 4, 221 85, Lund, Sweden; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund and Malmö, Sweden,Tumörmikromiljön,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Tumor microenvironment,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments(Swepub:lu)medk-mbe (författare)
  • Isaksson, KarolinLund University,Lunds universitet,Lunds Melanomstudiegrupp,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Lund Melanoma Study Group,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)kir-kis (författare)
  • Jernström, HelenaLund University,Lunds universitet,Epidemiologi och farmakogenetik,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Cancerepidemiologi & strål,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Epidemiology and pharmacogenetics,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Cancerepidemiology and radiation,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)onk-hje (författare)
  • Lund Univ, Dept Clin Sci Lund, Div Oncol, Barngatan 4, S-22185 Lund, Sweden.;Skane Univ Hosp, Barngatan 4, S-22185 Lund, Sweden.LUCC: Lunds universitets cancercentrum (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Breast Cancer Research and Treatment: Springer199:2, s. 335-3470167-68061573-7217

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy